Health Care & Life Sciences

CNO Financial earnings fall on recapitalization charge

October 29, 2012
 IBJ Staff
Carmel-based CNO Financial Group on Monday reported a third-quarter loss of $5 million compared to a $179.5 million profit in the third quarter of 2011.
More

Lilly's insulin dip concerns analysts

October 29, 2012
J.K. Wall
Eli Lilly and Co. suffered a tough week on the stock market, in part because of a disturbing bit of news buried in its third-quarter earnings report: Lilly’s insulin sales are down.
More

Outlook gloomy for device investments

October 29, 2012
J.K. Wall
The amount of venture capital invested in medical-device and equipment companies nationally has declined each quarter this year, reaching levels not seen since 2004, according to data released Oct. 19 by the National Venture Capital Association and PricewaterhouseCoopers.
More

Judge approves $90 million for Anthem plaintiffs

October 29, 2012
Kathleen McLaughlin
The settlement will go to 700,000 claimants in Indiana, Ohio, Kentucky and Connecticut, who said Anthem underpaid them when it converted in 2001 from policyholder ownership into publicly traded company WellPoint Inc.
More

Zimmer trims full-year forecast after quarterly profit falls

October 25, 2012
J.K. Wall
The Warsaw-based maker of orthopedic implants beat analysts’ estimates with its third-quarter earnings, but lowered its full-year forecast.
More

Lilly misses analyst estimates, lowers profit forecast

October 24, 2012
J.K. Wall
Third-quarter earnings at Eli Lilly and Co. fell short of analysts' expectations, and the Indianapolis-based drugmaker reduced its profit forecast by 4 cents per share for the remainder of the year.
More

Amerigroup shareholders approve $4.9B sale to WellPoint

October 24, 2012
J.K. Wall
Shareholders of Amerigroup Corp. overwhelming approved the Virginia company’s sale for $4.9 billion to Indianapolis-based health insurer WellPoint Inc. in a vote on Tuesday. The vote clears the way for the acquisition to close before the end of the year.
More

Lilly CEO calls for life sciences research institute

October 23, 2012
J.K. Wall
Eli Lilly CEO John Lechleiter on Tuesday called for creation of a "world-class" research institute in Indianapolis to bring together scientists from universities and corporations to develop new medical therapies and companies.
More

Roche continues to restructure diabetes unit

October 22, 2012
J.K. Wall
Roche officials said last week that price competition and lower reimbursement rates are forcing it to make an unspecified number of cuts in its U.S. sales force and at its research and development hubs in Indianapolis and Germany.
More

Lilly continues string of positive trials

October 22, 2012
J.K. Wall
Eli Lilly and Co. is continuing a string of positive yet incomplete clinical trial results, giving it a boost among investors.
More

Lilly says experimental diabetes drug outperformed rivals

October 22, 2012
J.K. Wall
Eli Lilly and Co. said dulaglutide lowered blood sugar better than three existing diabetes drugs in three Phase 3 clinical trials. Analysts expect the drug to hit the market in 2014 or 2015 and become a blockbuster.
More

Indianapolis tech firms, hospitals discover mutual needRestricted Content

October 20, 2012
Chris O'Malley
An initiative is matching tech entrepreneurs with hospital officials in the hope of solving health care problems.
More

Alzheimer’s prevention seen promising as drug cures fail

October 19, 2012
Bloomberg News
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
More

Lawsuit claims Aspen Dental clinics operating illegally

October 18, 2012
Associated Press
A federal lawsuit filed in New York claims Aspen Dental Management and the private equity firm that controls it illegally operate dental clinics across the country. The company operates 29 offices in Indiana.
More

Can Lilly capitalize on Alzheimer's breakthrough?

October 15, 2012
J.K. Wall
Eli Lilly and Co. has apparently made major medical history by being the first to develop a drug that alters the course of Alzheimer’s disease. But whether Lilly can be the first to make major money from a disease-altering Alzheimer’s drug is still in doubt.
More

Firm sees sterilization as fertile business ground

October 15, 2012
J.K. Wall
Indianapolis-based medical-device maker Catheter Research Inc. will receive a new kind of sterilization machine in December that it hopes will reduce costs and wait times for medical-device companies in the Midwest—including itself.
More

Lilly stomach-cancer drug helps survival, study finds

October 15, 2012
Bloomberg News
Eli Lilly and Co. shares rose nearly 5 percent Monday morning after it said a study found that its experimental stomach-cancer drug helped patients with advanced disease live longer.
More

Evans to lead AIT again as CEO leaves company

October 15, 2012
 IBJ Staff
Ron Thieme, who took over as president and CEO of AIT Laboratories during a management shakeup earlier this year, is leaving the company, the Indianapolis-based firm announced Monday morning.
More

Small law firm sees faith in WellPoint class-action suit pay offRestricted Content

October 13, 2012
Greg Andrews
A federal judge in June granted preliminary approval to a deal under which WellPoint Inc. would pay $90 million to settle a lawsuit charging it undercompensated policyholders when it converted into a public company in 2001.
More

WellPoint reorganizes into four business units

October 11, 2012
Bloomberg News
Separate Medicare and Medicaid divisions each will sell plans for those government-backed insurance programs. Another will handle commercial and individual business, and a specialty unit will provide dental, vision and disability coverage.
More

Lilly, Roche drugs chosen for Alzheimer’s prevention trial

October 10, 2012
Bloomberg News
Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
More

Lilly shares rise on Alzheimer's study results

October 8, 2012
J.K. Wall
Eli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease, according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than 5 percent on the news.
More

Study: Newly insured to be poorer, less educated

October 8, 2012
J.K. Wall
New health insurance coverage created by the 2010 health reform law will attract a lower-income, less-educated and more diverse set of customers than the insurance markets that exist today, according to a new analysis by PricewaterhouseCoopers. And that could create challenges for doctors and hospitals trying to care for those patients.
More

Lilly counting on diabetes products to challenge larger rivals

October 8, 2012
Bloomberg News
Eli Lilly and Co. is betting on a “broad” range of diabetes products including pills, insulins and a once-a-week treatment to take on bigger competitors, said Enrique Conterno, president of Lilly Diabetes.
More

New Alzheimer's unit stresses soothing elementsRestricted Content

October 6, 2012
Scott Olson
The 36-room wing at Hoosier Village Retirement Center includes antiques and minimizes confusing shadows among other design elements.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT